Skip to main content
SpringerLink
Log in

Tolerability of Postexposure Antiretroviral Prophylaxis for Occupational Exposures to HIV

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

A substantial body of evidence provides support (but not definitive proof of efficacy) for the use of antiretroviral agents as postexposure prophylaxis for occupational exposures to HIV in the healthcare workplace. Despite the lack of definitive evidence of the efficacy of these agents in this setting, over the past decade this intervention has become the standard of care for healthcare workers who sustain occupational exposures to HIV.

Administration of these agents — even for a relatively short 28-day postexposure course — is often fraught with difficulty. All of the agents currently used for postexposure prophylaxis regimens have substantial adverse effects, and significant adverse effects occur in more than two-thirds of individuals electing prophylaxis. This manuscript reiterates current US Federal Government guidelines for the administration of postexposure prophylaxis, specifically noting that zidovudine plus lamivudine (with or without a protease inhibitor) remains the recommended regimen. The paper summarises the significant toxicities associated with nucleoside reverse transcriptase inhibitors (primarily nausea, vomiting, diarrhoea and bone marrow suppression), non-nucleoside reverse transcriptase inhibitors (rash, fever, gastrointestinal symptoms and hepatitis, including hepatic decompensation necessitating liver transplantation) and protease inhibitors (nausea, vomiting, diarrhoea, abdominal pain, hyperglycaemia, hyperlipidaemia, headache and anorexia).

As a class, the antiretroviral agents have an extraordinary number of drug interactions. The non-nucleoside reverse transcriptase inhibitors and the protease inhibitors are metabolised through the cytochrome P450 pathway, and the effects of concomitant administration of protease inhibitors with other agents in the same class are discussed, as well as the effects of concomitant administration of protease inhibitors with non-nucleoside agents. The potential for numerous and medically risky drug interactions emphasises the importance of planning antiretroviral prophylaxis in consultation with practitioners or clinical pharmacists who are skilled in the use of these agents and knowledgeable about the potential for significant drug interactions that could either reduce the benefit of prophylaxis or increase the potential for toxicity.

Another common problem encountered by individuals managing postexposure prophylaxis programmes relates to the administration of chemoprophylaxis to a pregnant healthcare worker who has sustained an occupational exposure to HIV. We address what is known about the potential for toxicity and emphasise the recently published warning concerning the deaths of pregnant women and their offspring from lactic acidosis while receiving regimens containing stavudine and didanosine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Henderson DK, Fahey BJ, Saah AJ, et al. Longitudinal assessment of the risk for occupational/nosocomial transmission of human immunodeficiency virus, type I in health careworkers. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Oct 23-26; Los Angeles

  2. Henderson DK, Beekmann SE, Gerberding JL, editors. yPostexposure antiviral chemoprophylaxis following occupational exposure to the human immunodeficiency virus. Philadelphia (PA): JB Lippincott Co.; 1990. In: DeVita VT, Hellman S, Rosenberg SA, editors. AIDS Updates: AIDS - etiology, diagnosis, treatment, and prevention. 3rd ed. Philadelphia (PA): JB Lippencott Co., 1988: 1–12

    Google Scholar 

  3. Henderson DK, Gerberding JL. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: an interim analysis. J Infect Dis 1989; 160(2): 321–7

    Article  PubMed  CAS  Google Scholar 

  4. Para MF. Use of zidovudine following occupational exposure to human immunodeficiency virus. Clin Infect Dis 1992; 15(5): 884–5

    Article  PubMed  CAS  Google Scholar 

  5. Robinson Jr EN. Arguments against the chemoprophylactic use of zidovudine following occupational exposure to the human immunodeficiency virus. Clin Infect Dis 1993; 16(3): 357–60

    Article  PubMed  Google Scholar 

  6. Tamin J, Menzies D, Gilbert D, et al. Zidovudine after occupational exposure to HIV. BMJ 1991; 303(6802): 581

    Article  Google Scholar 

  7. Henderson DK. HIV postexposure prophylaxis in the 21st century. Emerg Infect Dis 2001; 7(2): 254–8. Available from URL: http://www.cdc.gov/ncidod/eid/vol7no2/henderson.htm [Accessed 2001 Jun 18]

    Article  PubMed  CAS  Google Scholar 

  8. Henderson DK. Postexposure treatment of HIV - taking some risks for safety’s sake. N Engl J Med 1997; 337(21): 1542–3

    Article  PubMed  CAS  Google Scholar 

  9. Henderson DK. Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 1999; 281(10): 931–6

    Article  PubMed  CAS  Google Scholar 

  10. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72(5): 4265–73

    PubMed  CAS  Google Scholar 

  11. Black RJ. Animal studies of prophylaxis. Am J Med 1997; 102Suppl. 5B: 39–44

    Article  PubMed  CAS  Google Scholar 

  12. Böttiger D, Johansson NG, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997; 11(2): 157–62

    Article  PubMed  Google Scholar 

  13. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270(5239): 1197–9

    Article  PubMed  CAS  Google Scholar 

  14. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331(18): 1173–80

    Article  PubMed  CAS  Google Scholar 

  15. Bulterys M, Orloff S, Abrams E, et al. Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: a prospective cohort study in four US cities [abstract 15]. Presented at: Global strategies for the prevention of HIV transmission from mothers to infants; 1999 Sep 1-6; Toronto

  16. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339(20): 1409–14

    Article  PubMed  CAS  Google Scholar 

  17. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337(21): 1485–90

    Article  PubMed  CAS  Google Scholar 

  18. Katzenstein TL, Dickmeiss E, Aladdin H, et al. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis. Ann Intern Med 2000; 133(1): 31–4

    PubMed  CAS  Google Scholar 

  19. Puro V, Calcagno G, Anselmo M, et al. Transient detection of plasma HIV-1 RNA during postexposure prophylaxis. Infect Control Hosp Epidemiol 2000; 21(8): 529–31

    Article  PubMed  CAS  Google Scholar 

  20. Centers for Disease Control and Prevention. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Morb Mortal Wkly Rep 1990; 39 (no. RR): 1–14

    Google Scholar 

  21. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996; 45 (22): 468–80

    Google Scholar 

  22. Centers for Disease Control and Prevention. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-7): 1–33

    Google Scholar 

  23. Public Health Laboratory Service. New guidance on post exposure prophylaxis of health care workers exposed to HIV at work. Commun Dis Rep CDR Wkly 1997; 7 (27): 239

    Google Scholar 

  24. Public Health Laboratory Service. New guidelines on post exposure prophylaxis for HIV. Commun Dis Rep CDR Wkly 2000; 10 (35): 311, 314

    Google Scholar 

  25. Struble KA, Pratt RD, Gitterman SR. Toxicity of antiretroviral agents. Am J Med 1997; 102(5B): 65–7

    Article  PubMed  CAS  Google Scholar 

  26. Henry K, Acosta EP, Jochimsen E. Hepatotoxicity and rash associated with zidovudine and zalcitabine chemoprophylaxis. Ann Intern Med 1996; 124(9): 855

    PubMed  CAS  Google Scholar 

  27. D’Silva M, Leibowitz D, Flaherty JP. Seizure associated with zidovudine. Lancet 1995; 346(8972): 452

    Article  PubMed  Google Scholar 

  28. Spenatto N, Viraben R. Early lipodystrophy occurring during postexposure prophylaxis. Sex Transm Infect 1998; 74(6): 455

    PubMed  CAS  Google Scholar 

  29. Swotinsky RB, Steger KA, Sulis C, et al. Occupational exposure to HIV: experience at a tertiary care center. J Occup Environ Med 1998; 40(12): 1102–9

    PubMed  CAS  Google Scholar 

  30. Wang SA, Puro V. Toxicity of post-exposure prophylaxis for human immunodeficiency virus. In: Panlilio L, editor. Balliere’s Clin Infect Dis. Vol 5. London: Balliere-Tindall, Inc, 1999: 349–63

    Google Scholar 

  31. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA 2000 Dec; 284(21): 2723

    PubMed  CAS  Google Scholar 

  32. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures — worldwide, 1997–2000. MMWR Morb Mortal Wkly Rep 2001; 49 (51): 1153–6

  33. Fahrner R, Beekmann S, Koziol D, et al. Safety of zidovudine administered as post-exposure chemoprophylaxis to healthcare workers sustaining HIV-related occupational exposures. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 7; Orlando

  34. Fahrner R, Beekmann S, Koziol D, et al. Safety of zidovudine (ZDV) administered as post-exposure chemoprophylaxis to healthcare workers (HCW) after occupational exposures to HIV. VIIIth International Conference on AIDS; 1992 Jul 19-24; Amsterdam

  35. Beekmann SE, Fahrner R, Koziol DE, et al. Safety of zidovudine (AZT) administered as post-exposure chemoprophylaxis to healthcare workers (HCW) sustaining occupational exposures (OE) to HIV. 30th Annual Meeting of the Infectious Diseases Society of America; 1992 Oct 10-12; Anaheim

  36. Beekmann SE, Fahrner R, Koziol DE, et al. Safety of zidovudine (AZT) administered as postexposure chemoprophylaxis to healthcare workers (HCW) sustaining occupational exposures (OE) to HIV. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 16-18; New Orleans

  37. Beekmann SE, Fahrner R, Henderson DK, et al. Zidovudine safety and tolerance among uninfected healthcare workers: a brief update. Am J Med 1997; 102(5B): 63–4

    Article  PubMed  CAS  Google Scholar 

  38. Gerberding JL. Post-exposure prophylaxis for human immunodeficiency virus at San Francisco General Hospital. Am J Med 1997; 102: 85–9

    Article  PubMed  CAS  Google Scholar 

  39. Gerberding JL. HIV exposure risk assessment and prophylactic treatment. In: Sande MA, Volberding P, editors. The medical management of AIDS. Philadelphia (PA): W.B. Saunders, 1999

    Google Scholar 

  40. Puro V. Post-exposure prophylaxis for HIV infection. Italian registry of post-exposure prophylaxis. Lancet 2000; 355(9214): 1556–7

    Article  PubMed  CAS  Google Scholar 

  41. Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers: Italian study group on occupational risk of HIV and other bloodborne infections. Am J Infect Control 1995; 23(5): 273–7

    Article  PubMed  CAS  Google Scholar 

  42. Puro V, Ippolito G, Serafin I, et al. Update: zidovudine postexposure prophylaxis in Italy. The Italian study group occupational risk HIV infection. 9th International Conference on AIDS; 1993 Jun 7-11; Berlin

  43. Puro V, Ippolito G, Guzzanti E, et al. Zidovudine prophylaxis after accidental exposure to HIV: the Italian experience. The Italian study group on occupational risk of HIV infection. AIDS 1992; 6(9): 963–9

    Article  PubMed  CAS  Google Scholar 

  44. Puro V, Ippolito G. Zidovudine in post-exposure prophylaxis of health-care workers. Lancet 1990; 335(8698): 1166–7

    Article  PubMed  CAS  Google Scholar 

  45. Ippolito G, Puro V. The Italian registry of antiretroviral prophylaxis: zidovudine toxicity in uninfected healthcare workers. Am J Med 1997; 102(5B): 58–62

    Article  PubMed  CAS  Google Scholar 

  46. Forseter G, Joline C, Wormser GP. Tolerability, safety, and acceptability of zidovudine prophylaxis in health care workers. Arch Intern Med 1994; 154(23): 2745–9

    Article  PubMed  CAS  Google Scholar 

  47. Tokars J, Marcus R, Culver D, et al. Zidovudine (AZT) use after occupational HIV exposure: toxicity and failures reported to CDC. 9th International Conference on AIDS; 1993 Jun 7-11; Berlin

  48. Schmitz SH, Scheding S, Voliotis D, et al. Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann Hematol 1994; 69(3): 135–8

    Article  PubMed  CAS  Google Scholar 

  49. Sepkowitz KA, Rivera P, Louther J, et al. Postexposure prophylaxis for human immunodeficiency virus: frequency of initiation and completion of newly recommended regimen. Infect Control Hosp Epidemiol 1998; 19: 506–8

    Article  PubMed  CAS  Google Scholar 

  50. Fahrner R, Beekmann SE, Nelson L, et al. Combination Post-Exposure Prophylaxis (PEP): a prospective study of HIV-Exposed Health Care Workers (HCW). 12th International Conference on AIDS; 1998 Jun 28-Jul 3; Geneva

  51. Wang SA, Panlilio AL, Doi PA, et al. Experience of healthcare workers taking postexposure prophylaxis. Infect Control Hosp Epidemiol 2000; 21: 780–5

    Article  PubMed  CAS  Google Scholar 

  52. Puro V, Ippolito G. Issues on antiretroviral post exposure combination prophylaxis. J Biol Regul Homeost Agents 1997; 11(1-2): 11–9

    PubMed  CAS  Google Scholar 

  53. Martin JN, Roland ME, Bamberger JD, et al. Postexposure prophylaxis after sexual or drug use exposure to HIV: final results from the San Francisco Post Exposure Prevention Project. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco

  54. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354(9181): 795–802

    Article  PubMed  CAS  Google Scholar 

  55. Blanche S, Rouzioux C, Mandelbrot L et al. Zidovudine-Lamivudine for Prevention of Mother to Child HIV-1 Transmission. 6th Annual Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago

  56. Smyth AC. Important drug warning. Bristol-Myers Squibb Company. Available at: http://www.fda.gov/medwatch/safety/2001/pregwarnfinalbms.pdf. [Accessed 2001 March 12]

  57. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000; 355(9203): 547–8

    Article  PubMed  CAS  Google Scholar 

  58. Bangsberg D, Goldschmidt RH. Postexposure prophylaxis for occupational exposure to HIV. JAMA 1999; 282(17): 1623–4

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of the Deputy Director for Clinical Care, Warren G. Magnuson Clinical Center, Building 10, Room 2C146 National Institutes of Health, 10 Center Drive, MSC-1504, Bethesda, Maryland, 0892-1504, USA

    Laura M. Lee &  David K. Henderson

Authors
  1. Laura M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David K. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David K. Henderson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, L.M., Henderson, D.K. Tolerability of Postexposure Antiretroviral Prophylaxis for Occupational Exposures to HIV. Drug-Safety 24, 587–597 (2001). https://doi.org/10.2165/00002018-200124080-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124080-00003

Keywords

Search

Navigation